Tango Therapeutics Inc. (TNGX)
2.64
0.02 (0.76%)
At close: Jan 15, 2025, 12:53 PM
undefined% (undefined)
| Bid | 2.64 |
| Market Cap | 283.58M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.15 |
| PE Ratio (ttm) | -2.3 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.65 |
| Volume | 375,185 |
| Avg. Volume (20D) | 1,984,900 |
| Open | 2.66 |
| Previous Close | 2.62 |
| Day's Range | 2.62 - 2.80 |
| 52-Week Range | 2.58 - 13.01 |
| Beta | undefined |
About TNGX
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and ...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 3, 2020
Employees 140
Stock Exchange NASDAQ
Ticker Symbol TNGX
Website https://www.tangotx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for TNGX stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 392.42% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Tango Therapeutics Inc. is scheduled to release its earnings on Mar 17, 2025,
before market opens.
Analysts project revenue of $8.02M, reflecting a 47.67% YoY growth and earnings per share of -0.34, making a 6.25% increase YoY.
Analysts project revenue of $8.02M, reflecting a 47.67% YoY growth and earnings per share of -0.34, making a 6.25% increase YoY.
2 months ago ·
Source
-37.45%
Tango Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
10 months ago ·
Source
-7.09%
Tango Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.
